GSK is expected to achieve blockbuster status for its months-old RSV vaccine this week, stealing a march on rival Pfizer and begin allaying long-standing investor concerns about its pipeline.
葛兰素史克(GSK)有望在本周凭借其已上市数月的RSV疫苗获得重磅地位，从而在竞争对手辉瑞(Pfizer)面前抢得先机，并开始消除投资者对其产品线的长期担忧。
您已阅读5%（271字），剩余95%（5484字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。